Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats.

BACKGROUND The chronic inhibition of NO synthesis by N(omega)-nitro-L-arginine methyl ester (L-NAME) upregulates the cardiovascular tissue angiotensin II (Ang II)-generating system and induces cardiovascular inflammatory changes in rats. METHODS AND RESULTS We used a rat model to investigate the role of local Ang II activity in the pathogenesis of such inflammatory changes. Marked increases in monocyte infiltration into coronary vessels and myocardial interstitial areas, monocyte chemoattractant protein-1 (MCP-1) expression, and nuclear factor-kappaB (NF-kappaB, an important redox-sensitive transcriptional factor that induces MCP-1) activity were observed on day 3 of L-NAME administration. Along with these changes, vascular superoxide anion production was also increased. Treatment with an Ang II type 1 receptor antagonist or with a thiol-containing antioxidant, N-acetylcysteine, prevented all of these changes. CONCLUSIONS Increased Ang II activity mediated via the type 1 receptor may thus be important in the pathogenesis of early cardiovascular inflammatory changes in this model. Endothelium-derived NO may decrease MCP-1 production and oxidative stress-sensitive signals by suppressing localized activity of Ang II.

[1]  A. Takeshita,et al.  Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats. , 1999, Hypertension.

[2]  A. Takeshita,et al.  Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[3]  A. Takeshita,et al.  Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. , 1998, Hypertension.

[4]  A. Takeshita,et al.  Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. , 1997, Hypertension.

[5]  D. Harrison,et al.  Cellular and molecular mechanisms of endothelial cell dysfunction. , 1997, The Journal of clinical investigation.

[6]  P. Tsao,et al.  Nitric oxide regulates monocyte chemotactic protein-1. , 1997, Circulation.

[7]  J. Egido,et al.  Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. , 1997, Circulation.

[8]  S. Rajagopalan,et al.  Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. , 1997, Circulation.

[9]  K. Matsushima,et al.  Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP‐1) , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  M. Ushio-Fukai,et al.  p22phox Is a Critical Component of the Superoxide-generating NADH/NADPH Oxidase System and Regulates Angiotensin IIinduced Hypertrophy in Vascular Smooth Muscle Cells* , 1996, The Journal of Biological Chemistry.

[11]  J. Christman,et al.  In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. , 1996, Journal of immunology.

[12]  A. Chobanian,et al.  Effects of angiotensin II infusion and inhibition of nitric oxide synthase on the rat aorta. , 1996, Hypertension.

[13]  B. Rollins.  Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. , 1996, Molecular medicine today.

[14]  R. Alexander,et al.  Endothelial control of the cardiovascular system: recent advances , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  H. Koike,et al.  Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. , 1995, European journal of pharmacology.

[16]  G. Natoli,et al.  Reactive Oxygen Intermediates Mediate Angiotensin II-induced c-Jun•c-Fos Heterodimer DNA Binding Activity and Proliferative Hypertrophic Responses in Myogenic Cells (*) , 1995, The Journal of Biological Chemistry.

[17]  P. Libby,et al.  Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. , 1995, The Journal of clinical investigation.

[18]  P. Libby,et al.  Induction and Stabilization of IκBα by Nitric Oxide Mediates Inhibition of NF-κB (*) , 1995, The Journal of Biological Chemistry.

[19]  R. Busse,et al.  Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. , 1995, Circulation research.

[20]  Y. Kaneda,et al.  Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Sugimachi,et al.  Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Different responses to acetylcholine and substance P. , 1995, Hypertension.

[22]  P. Kubes,et al.  Intracellular oxidative stress induced by nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils. , 1994, Circulation research.

[23]  J. Michel,et al.  Colocalization of myocardial fibrosis and inflammatory cells in rats. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[24]  A M Zeiher,et al.  Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. , 1993, The Journal of clinical investigation.

[25]  M. Sugimachi,et al.  Effects of Age on Endothelium‐Dependent Vasodilation of Resistance Coronary Artery by Acetycholine in Humans , 1993, Circulation.

[26]  E. Leonard,et al.  Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. , 1993, Human pathology.

[27]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[28]  P. Tsao,et al.  Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. , 1992, The Journal of clinical investigation.

[29]  D. Steinberg,et al.  Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[30]  W. Schürch,et al.  Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[31]  A. Yeung,et al.  Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. , 1990, Circulation.

[32]  A. Takeshita,et al.  Hideharu Tomita , Hiroaki Oxide Synthesis in Rats Cardiac Angiotensin II Receptors Are Upregulated by Long-Term Inhibition of Nitric , 1998 .

[33]  A. Takeshita,et al.  Downregulation of angiotensin II type 1 receptor gene transcription by nitric oxide. , 1998, Hypertension.

[34]  竹本 真生.  Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats , 1998 .

[35]  R. Alexander,et al.  Angiotensin II signaling in vascular smooth muscle. New concepts. , 1997, Hypertension.

[36]  P. Libby,et al.  Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. , 1995, The Journal of biological chemistry.

[37]  Von der Leyen.  Gene therapy inhibiting neointimal vascular lesion , 1995 .

[38]  坂梨 祐司.  Kinetics of macrophage subpopulations and expression of monocyte chemoattractant protein-1 (MCP-1) in bleomycin-induced lung injury of rats studied by a novel monoclonal antibody against rat MCP-1 , 1994 .

[39]  M. Sugimachi,et al.  Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. , 1993, The Journal of clinical investigation.

[40]  P. Libby,et al.  Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[41]  N. Brachfeld.  CORONARY VASOMOTOR RESPONSE TO PHARMACOLOGIC AGENTS. , 1964, The American journal of cardiology.